University of Michigan Rogel Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Michigan Rogel Cancer Center sits in the top decile of US sponsors by registered trial count (#118 of 15,742 sponsors by registered trial count).
University of Michigan Rogel Cancer Center: 292 sponsored US clinical trials, 45 recruiting.
University of Michigan Rogel Cancer Center sponsors 292 registered US clinical trials on ClinicalTrials.gov, 45 of them currently recruiting, and 167 completed. 4 of these trials are in Phase 3-4 (later-stage) and 182 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 12 trials.
Top-decile sponsor footprint
University of Michigan Rogel Cancer Center ranks in the top decile of sponsors by registered trial count (#118 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
167 of 229 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (72.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
292 total, page 6 of 6
Evaluation of Side Effects and Relative Activity of Two Chemotherapy Regimens in the Treatment Soft Tissue Sarcoma
NCT00189137
Study of Etanercept for the Prevention of Complications Resulting From Hematopoietic Stem Cell Transplantation (HSCT)
NCT00141739
Computer-Based Tailored or Standard Information for Colorectal Cancer Screening
NCT00955188
Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma
NCT00135187
Gemcitabine, Oxaliplatin and Radiation Therapy in Pancreatic Cancer
NCT00242190
Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma
NCT00115739
The Use of Etanercept (Enbrel®) in the Treatment of Acute Graft-Versus-Host Disease
NCT00141713
Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant
NCT00141726
Optimized Intensity Modulated Irradiation for Head and Neck Cancer
NCT00580983
Evaluation of Tumor Factors in Breast Cancer Treated With Docetaxel and Capecitabine
NCT00156312
Combination Chemotherapy Treatments in Patients With Metastatic Colorectal Cancer
NCT00230399
UMCCOP 02-01 Ginger in Treating Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer
NCT00064272
Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant
NCT00143845
Gemcitabine, Cisplatin, and Celecoxib Treatment of Metastatic Pancreatic Cancer
NCT00176813
Docetaxel Plus Capecitabine in Newly Diagnosed Localized or Locally Advanced Prostate Cancer
NCT00151047
Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's Lymphoma
NCT00141700
Feasibility Study of Evaluating Breast Cancer Patients With Ductal Lavage
NCT00156260
A Study of a New Combination and Schedule of Chemotherapy Drugs for the Treatment of Head and Neck Cancer
NCT00148122
Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate
NCT00151073
Gleevec Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive Extensive SCLC
NCT00156286
Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer
NCT00151086
Curcumin for the Prevention of Colon Cancer
NCT00027495
Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma
NCT00176800
Tetrathiomolybdate in Hormone Refractory Prostate Cancer
NCT00150995
Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary Site
NCT00148135
Study of Rituximab Plus High-Dose Chemotherapy Non-Hodgkin's Lymphoma
NCT00143871
Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal Carcinoma
NCT00176774
Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome
NCT00005598
Radiation Therapy With Capecitabine in Rectal Cancer
NCT00176787
Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer
NCT00151034
Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood
NCT00146055
Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the Blood
NCT00143884
Tumor-Pulsed Dendritic Cells Used as a Tumor Vaccine
NCT00176761
Paclitaxel, Carboplatin and Gemcitabine in the Treatment of Patients With Advanced Transitional Cell Cancer of the Bladder
NCT00136175
Phase II Study of Tailored-Dose Docetaxel in Metastatic Breast Cancer
NCT00148070
UMCC 9901: Phase II Study of Tailored-Dose Docetaxel + Trastuzumab in Her-2 Positive Metastatic Breast Cancer
NCT00146042
UMCC 9609 Tretinoin in Preventing Cancer of the Cervix in Patients With Cervical Neoplasia
NCT00003598
Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate
NCT00151060
Pre-operative Chemotherapy and Radiation Therapy for Esophageal Carcinoma
NCT00230451
Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers
NCT00141765
Eflornithine to Prevent Cancer in Patients With Barrett's Esophagus
NCT00003076
Companion Pharmacogenetic Study to UMCC 9900/9901
NCT00146029
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 56 |
| Phase 2 | 126 |
| Phase 3 | 2 |
| Phase 4 | 2 |
What is open in the University of Michigan Rogel Cancer Center pipeline
45 recruiting of 292 indexed (15% open); 167 completed (57%).
Phase mix: 4 late (III/IV) vs 182 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Michigan Rogel Cancer Center: open-pipeline peers nationwide
Peers matched on 292 registered trials and 15% open enrollment, not the therapeutic-area sidebar.
University of Michigan Rogel Cancer Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 292 trials (± recruiting share)
- Thomas Jefferson University · 292 trials · 18% recruiting
- University of Missouri-Columbia · 291 trials · 19% recruiting
- Kaiser Permanente · 294 trials · 7% recruiting
- Eisai · 287 trials · 2% recruiting
Sponsors near 15% open enrollment (± trial volume)
- Nationwide Children's Hospital · 15% recruiting · 188 trials
- Arrowhead Regional Medical Center · 15% recruiting · 13 trials
- Aurinia Pharmaceuticals · 15% recruiting · 13 trials
- Bronx VA Medical Center · 15% recruiting · 13 trials
Related
What to do with this University of Michigan Rogel Cancer Center page
292 registered trials is a research-attention snapshot, not an endorsement of University of Michigan Rogel Cancer Center or any single study.
- 45 of University of Michigan Rogel Cancer Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition University of Michigan Rogel Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Michigan Rogel Cancer Center pipeline card: 292 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.